|Bid||8.86 x 900|
|Ask||9.06 x 2200|
|Day's Range||8.74 - 9.37|
|52 Week Range||3.41 - 23.66|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential impact of increased NAD+ levels on patients with citrin deficiency. The first study, led by Prof. Paul M. Yen and other scientists at Duke-NUS Medical School in Singapore, will examine the ability of NR to impact mitochondrial function, lipid accumulation, inflammation, and fibrosis in the liver using preclinical models of citrin deficiency.
ChromaDex Corporation ( NASDAQ:CDXC ), is not the largest company out there, but it led the NASDAQCM gainers with a...
ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference.